Last reviewed · How we verify
HepA-I
HepA-I is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
HepA-I is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in children and adults.
At a glance
| Generic name | HepA-I |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus (HAV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus particles that trigger both humoral and cellular immune responses, leading to the production of protective antibodies (anti-HAV IgG) and memory B cells. This provides long-term immunity against hepatitis A infection without causing disease.
Approved indications
- Prevention of hepatitis A infection in children and adults
Common side effects
- Injection site pain or swelling
- Fever
- Headache
- Fatigue
Key clinical trials
- Booster Dose of sIPV Co-administered With MMR and HepA-I. (PHASE4)
- Phase IV Study of Concomitant Administration of the sIPV and HepA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HepA-I CI brief — competitive landscape report
- HepA-I updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI